Table 3 Comparison of Effective Dose for CT Brain Studies Between Pediatric and General EDs
Age Group | Overall (n = 479) | Pediatric ED (n = 379) | General EDs (n = 100) | p-value | |||
|---|---|---|---|---|---|---|---|
Median Effective Dose (IQR), mSv | n (%) | Median Effective Dose (IQR), mSv | n (%) | Median Effective Dose (IQR), mSv | n (%) | ||
≤6 months | 1.84 (1.60–2.65) | 22 (4.6) | 1.79 (1.59–2.39) | 20 (5.3) | 2.95 (−) | 2 (2.0) | 0.052 |
> 6 months to ≤3 years | 1.97 (1.67–2.29) | 118 (24.6) | 1.97 (1.67–2.26) | 112 (29.6) | 2.57 (1.76–4.01) | 6 (6.0) | 0.063 |
> 3 years to ≤6 years | 1.57 (1.42–1.57) | 87 (18.2) | 1.57 (1.42–1.79) | 82 (21.6) | 1.93 (1.51–2.28) | 5 (5.0) | 0.047 |
> 6 years to ≤10 years | 1.48 (1.30–1.76) | 88 (18.4) | 1.43 (1.27–1.67) | 72 (19.0) | 1.94 (1.61–2.59) | 16 (16.0) | 0.002 |
> 10 years | 1.63 (1.38–2.10) | 164 (34.2) | 1.68 (1.32–1.72) | 93 (24.5) | 2.03 (1.58–2.88) | 71 (71.0) | < 0.001 |